Drug Profile
Fomepizole oral - Horizon Therapeutics plc
Alternative Names: 4-Methylpyrazole; 4-MP - Horizon Therapeutics plc; ConviviaLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Convivia
- Developer Horizon Therapeutics plc
- Class Antidotes; Pyrazoles; Small molecules
- Mechanism of Action Alcohol dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Metabolic disorders
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 01 Sep 2015 Clinical development is ongoing in the USA
- 12 Aug 2014 Fomepizole oral is still in phase II development for Metabolic disorders